Healthcare Resource Utilization (Hcru) in Patients Receiving Ipilimumab for Advanced Melanoma: Impact of Survival and Eastern Cooperative Oncology Group (Ecog) Status

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)

“…Tarhini et al conducted a retrospective chart review of stage IV patients receiving first‐line ipilimumab in the U.S. and observed high hospitalization rates for short‐term survivors and a considerable increase in health care costs associated with grade 3 or 4 adverse events . Costs of imaging or concomitant medications used to manage immune‐related adverse events, such as colitis or hypophysitis, were not considered . There is heterogeneity across studies with regard to study settings, populations, and approaches to describe HCRU and associated costs related to these treatments.…”

The relationship between Eastern Cooperative Oncology Group performance status and healthcare resource utilization among patients with advanced or metastatic colorectal, lung or gastric cancer

“…These data suggest that the underlying health of the patient, and perhaps not PS, is an important factor associated with resource use for all patients included in this study, as the result was consistent among those with colorectal, lung or gastric cancer. Underlying health conditions may play an important role in the relationship between PS and HCRU; a relationship was observed only among those with survival outcomes of less than 1 year in melanoma; unfortunately no data were presented related to comorbid conditions in this study, which may have helped to explain this relationship 17 .…”

“…Underlying health conditions may play an important role in the relationship between PS and HCRU; a relationship was observed only among those with survival outcomes of less than one year in melanoma; unfortunately no data were presented related to comorbid conditions in this study, which may have helped to explain this relationship. [20] There were no strong correlations identified that might suggest decreased HCRU for patients whose PS is improved. However, due to the small number of patients particularly in the gastric cancer cohort, subsequent lack power, and lack of recordings of varying in PS score within patients over time, the possibility that this relationship exists cannot be ruled out.…”